KYIV. Sept 8 (Interfax-Ukraine) – Biofarma LLC (Kyiv) in two or three years would be able to start producing antitetanus immunoglobulinin, the company has told Interfax-Ukraine.
“We are ready to start designing antitetanus immunoglobulinin if the country needs it. We have production technologies. We understand how to do this. We would be able to produce in two or three years,” Deputy Director for Science and Technologies at Biofarma Vitaliy Karbovsky said.
The Health Ministry told Interfax-Ukraine that Biofarma and blood donor centers are able to produce these immunoglobulinins.
“Negations are underway. There is certain progress. Immunoglobulinins can be made in Ukraine,” the ministry said.
Biofarma is in the top ten largest Ukrainian drug manufactures. Biofarma produces more than 20 immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.
